domingo, 26 de noviembre de 2017

Analysis of factors influencing molecular testing at diagnostic of colorectal cancer. - PubMed - NCBI

Analysis of factors influencing molecular testing at diagnostic of colorectal cancer. - PubMed - NCBI



 2017 Nov 14;17(1):765. doi: 10.1186/s12885-017-3759-6.

Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.

Abstract

BACKGROUND:

The aim of the study was to evaluate the current rate of molecular testing prescription (KRAS codons 12/13, BRAF and microsatellite instability (MSI)) in newly diagnosed colorectal cancer (CRC) patients and to determine which factors influence testing.

METHODS:

All incident CRC cases in 2010 were identified in the Poitou-Charentes General Cancer Registry. The exhaustive molecular testing performed was accessed in the French molecular genetics platform. Factors influencing prescription were analyzed using logistic regression.

RESULTS:

Among the 1269 CRCs included in the study, KRAS, BRAF and MSI testing accounted for 35.1%, 10.5% and 10.9%, respectively. KRAS testing was carried out in 65.5% of metastatic CRCs, and 26.1% of non-metastatic CRCs. Among metastatic CRCs, age (<60 years), site of primary tumour (left colon) and geographical area of treatment were factors related to KRAS testing. BRAF testing was contemporary to KRAS testing for 92.5% of patients. Factors related to MSI testing were age (<60 years), TNM stage (stage IV) and geographical area of treatment. Among CRC patients under 60 years old, only 37.5% had MSI testing.

CONCLUSION:

These results underscore the need to reduce disparities in CRC molecular testing and highlight the limited application of the French guidelines, especially concerning MSI testing.

KEYWORDS:

BRAF; Colorectal cancer; KRAS; Microsatellite instability; Molecular testing; Mutation

PMID:
 
29137623
 
PMCID:
 
PMC5686889
 
DOI:
 
10.1186/s12885-017-3759-6

No hay comentarios:

Publicar un comentario